KEYNOTE-826
21 Dec 2020
Trial Summary
The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) plus one of four platinum-based chemotherapy regimens compared to the efficacy and safety of placebo plus one of four platinum-based chemotherapy regimens in the treatment of persistent, recurrent, or metastatic cervical cancer
Acronym:
KEYNOTE-826
ACTRN/NCT /ethics:
NCT03635567
Scientific title:
Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)
Sponsor / Cooperative group:
Merck Sharp & Dohme Corp.
Trial & Patient Characteristics
| Cancer Type | Gynaecological |
|---|---|
| Trial Type | Treatment |
| Phase | Phase III |
| Age Range | 18 years and older |
| Sex | Female |
| Tumour Stream | - |
| Cancer Stage | Locally Recurrent or Locally Advanced, Metastatic or Widespread |
| Anticipated Start Date | 2018-10-25 |
| Anticipated End Date | 2022-11-23 |
Participating Hospitals
| Hospital | Flinders Medical Centre |
|---|---|
| Clinical Trial Coordinator | Alex Scott-Hoy |
| alex.scott-hoy@sa.gov.au | |
| Phone | 08 8204 4830 |
| Principal Investigator | Dr Ganessan Kichenadasse |
| Recruitment Status | Recruitment on Hold |